Lilly Officially Opens Diabetes R&D Facility in Shanghai

Yesterday, Lilly held the official opening of its first-ever research facility in China, which will be known as the Lilly China Research and Development Center (LCRDC). The LCDRC will be devoted to discovering innovative diabetes treatments, with an eye toward specific China variations of the disease. The goal will be to slow progression of the disease. The Center will employ 150 researchers and staff, most of whom were hired in China. More details.... Stock Symbol: (NYSE: LLY) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});